| | | | | 1 | | | |
| | | | | 1 | | | |
| | | | | 9 | | | |
| | | | | 16 | | | |
| | | | | 18 | | | |
| | | | | 24 | | | |
| | | | | 41 | | | |
| | | | | 60 | | | |
| | | | | 64 | | | |
| | | | | 66 | | | |
| | | | | 68 | | | |
| | | | | 70 | | | |
| | | | | 71 | | | |
| | | | | 71 | | | |
| | | | | A-1 | | | |
| | | | | B-1 | | | |
| | | | | C-1 | | |
(in millions, except for share and per share amounts)
|
| |
Low
|
| |
High
|
| ||||||
Cash and cash equivalents as of March 31, 2024
|
| | | $ | 3.49 | | | | | $ | 3.49 | | |
Purchase price from Immunome
|
| | | $ | 5.50 | | | | | $ | 5.50 | | |
Estimated Proceeds, Expenses and Cash Reserves | | | | | | | | | | | | | |
Operating expenses after March 31, 2024(1)
|
| | | $ | (0.74) | | | | | $ | (0.64) | | |
Assumed severance for executive officers(2)
|
| | | $ | (1.41) | | | | | $ | (1.41) | | |
Assumed severance for other employees(3)
|
| | | $ | (0.24) | | | | | $ | (0.24) | | |
Accounts payable and accrued liabilities(4)
|
| | | $ | (1.24) | | | | | $ | (1.01) | | |
Insurance(5) | | | | $ | (1.37) | | | | | $ | (1.37) | | |
Professional fees (attorneys, accountants, consultants)(6)
|
| | | $ | (0.30) | | | | | $ | (0.30) | | |
Reserve for potential or unanticipated claims and contingencies
|
| | | $ | (1.00) | | | | | $ | (1.00) | | |
Reserve for MAM01/ATRC-501 post asset sale close
|
| | | $ | (0.40) | | | | | $ | (0.40) | | |
Reserve for remaining asset intellectual property prosecution and maintenance
|
| | | $ | (0.22) | | | | | $ | (0.22) | | |
Total
|
| | | $ | (6.93) | | | | | $ | (6.60) | | |
Estimated cash to distribute to stockholders
|
| | | $ | 2.06 | | | | | $ | 2.39 | | |
Assumed shares outstanding(7)
|
| | | | 39,653,242 | | | | | | 39,653,242 | | |
Estimated initial liquidating distribution per share
|
| | | $ | 0.05 | | | | | $ | 0.06 | | |
Name
|
| |
Cash
Severance Payment |
| |
COBRA
Benefits |
| |
Accelerated
Vesting of Equity Awards |
| |
Aggregate
Severance Benefits |
| ||||||||||||
John A. Orwin
|
| | | $ | 625,039 | | | | | $ | 42,912 | | | | | | — | | | | | $ | 667,951 | | |
Courtney J. Phillips
|
| | | $ | 337,500 | | | | | | — | | | | | | — | | | | | $ | 337,500 | | |
Tito A. Serafini, Ph.D.(1)
|
| | | $ | 377,961 | | | | | $ | 32,181 | | | | | $ | 1,458(2) | | | | | $ | 411,600 | | |
Stephen E. Gould, Ph.D.(3)
|
| | | $ | 356,250 | | | | | $ | 32,181 | | | | | | — | | | | | $ | 388,431 | | |
Philippe M. Bishop, M.D.(4)
|
| | | $ | 356,250 | | | | | $ | 10,323 | | | | | | — | | | | | $ | 366,573 | | |
Name
|
| |
Cash
Severance Payment |
| |
Bonus
Payment |
| |
COBRA
Benefits |
| |
Aggregate
Deferred and Contingent Severance Benefits |
| ||||||||||||
John A. Orwin
|
| | | $ | 312,520 | | | | | $ | 515,657(1) | | | | | $ | 21,456 | | | | | $ | 849,633 | | |
Tito A. Serafini, Ph.D.
|
| | | $ | 125,987 | | | | | $ | 201,579(2) | | | | | $ | 10,728 | | | | | $ | 338,294 | | |
Courtney J. Phillips
|
| | | $ | 112,500 | | | | | $ | 180,000(3) | | | | | $ | 1,083 | | | | | $ | 293,583 | | |
Name
|
| |
Number of Shares of
Class A Common Stock Owned(1) |
| |||
John A. Orwin(2)
|
| | | | 77,541 | | |
Courtney J. Phillips
|
| | | | 28,764 | | |
Brian Atwood
|
| | | | 49,654 | | |
Kristine M. Ball
|
| | | | — | | |
Franklin Berger
|
| | | | 97,808 | | |
David Lacey, M.D.
|
| | | | — | | |
William H. Robinson, M.D., Ph. D.
|
| | | | 368,948 | | |
Stacey Ma, Ph.D.
|
| | | | — | | |
Stephen Brady
|
| | | | — | | |
Lindsey Rolfe, M.D.
|
| | | | — | | |
Tito A. Serafini, Ph.D.
|
| | | | 322,511 | | |
| | |
Shares Beneficially Owned
|
| |||||||||||||||||||||
Beneficial Owner
|
| |
Number of
shares of Class A common stock |
| |
Percentage of
shares of Class A common stock |
| |
Number of
shares of Series A Junior Preferred Stock |
| |
Percentage of
shares of Series A Junior Preferred Stock |
| ||||||||||||
Greater than 5% Stockholders | | | | | | | | | | | | | | | | ||||||||||
Entities Affiliated with Baker Brothers Life Sciences, L.P.(1)
|
| | | | 7,677,982(2) | | | | | | 19.9% | | | | | | — | | | | | | — | | |
Entities Affiliated with Boxer Capital, LLC(3)
|
| | | | 2,202,333 | | | | | | 5.7% | | | | | | — | | | | | | — | | |
Directors and Named Executive Officers
|
| | | | | | | | | | | | | | | | | | | | | | | | |
John A. Orwin(4)
|
| | | | 77,541 | | | | | | * | | | | | | 1 | | | | | | 100% | | |
Tito A. Serafini, Ph.D.(5)
|
| | | | 322,511 | | | | | | * | | | | | | — | | | | | | — | | |
Brian Atwood(6)
|
| | | | 49,654 | | | | | | * | | | | | | — | | | | | | — | | |
Kristine M. Ball
|
| | | | — | | | | | | — | | | | | | — | | | | | | — | | |
Franklin Berger(7)
|
| | | | 97,808 | | | | | | * | | | | | | — | | | | | | — | | |
Stephen R. Brady
|
| | | | — | | | | | | — | | | | | | — | | | | | | — | | |
David Lacey, M.D.
|
| | | | — | | | | | | — | | | | | | — | | | | | | — | | |
Stacey Y. Ma, Ph.D.
|
| | | | — | | | | | | — | | | | | | — | | | | | | — | | |
William Robinson, M.D., Ph.D.(8)
|
| | | | 368,948 | | | | | | * | | | | | | — | | | | | | — | | |
Lindsey Rolfe, MBChB
|
| | | | — | | | | | | — | | | | | | — | | | | | | — | | |
Stephen E. Gould(9)
|
| | | | 6,757 | | | | | | * | | | | | | — | | | | | | — | | |
All executive officers and directors as a group (11 persons)(10)
|
| | | | 945,226 | | | | | | 2.5% | | | | | | 1 | | | | | | 100% | | |
| | |
Page
|
| |||
| | | | A-1 | | | |
| | | | A-1 | | | |
| | | | A-9 | | | |
| | | | A-9 | | | |
| | | | A-9 | | | |
| | | | A-11 | | | |
| | | | A-11 | | | |
| | | | A-11 | | | |
| | | | A-12 | | | |
| | | | A-12 | | | |
| | | | A-12 | | | |
| | | | A-18 | | | |
| | | | A-19 | | | |
| | | | A-19 | | | |
| | | | A-20 | | | |
| | | | A-20 | | | |
| | | | A-20 | | | |
| | | | A-20 | | | |
| | | | A-21 | | | |
| | | | A-21 | | | |
| | | | A-21 | | | |
| | | | A-21 | | | |
| | | | A-21 | | | |
| | | | A-21 | | | |
| | | | A-21 | | | |
| | | | A-22 | | | |
| | | | A-23 | | | |
| | | | A-23 | | | |
| | | | A-23 | | | |
| | | | A-27 | | | |
| | | | A-27 | | | |
| | | | A-28 | | | |
| | | | A-28 | | | |
| | | | A-29 | | | |
| | | | A-29 | | | |
| | | | A-29 | | | |
| | | | A-30 | | | |
| | | | A-30 | | | |
| | | | A-30 | | | |
| | | | A-30 | | | |
| | | | A-30 | | |
| | |
Page
|
| |||
| | | | A-30 | | | |
| | | | A-31 | | | |
| | | | A-31 | | | |
| | | | A-31 | | | |
| | | | A-31 | | | |
| | | | A-32 | | | |
| | | | A-32 | | | |
| | | | A-32 | | | |
| | | | A-32 | | | |
| | | | A-32 | | | |
| | | | A-33 | | | |
| | | | A-33 | | | |
| | | | A-34 | | | |
| | | | A-34 | | | |
| | | | A-34 | | | |
| | | | A-34 | | | |
| | | | A-34 | | | |
| | | | A-34 | | | |
| | | | A-34 | | | |
| | | | A-34 | | | |
| | | | A-35 | | |
| SCHEDULES | | | | |
|
Schedule 2.1.2(a)
Assumed Contracts
|
| | | |
|
Schedule 2.1.2(b)
Seller IP
|
| | | |
|
Schedule 2.1.2(e)
Regulatory Approvals
|
| | | |
|
Schedule 2.1.2(f)
Specified Samples
|
| | | |
|
Schedule 2.1.4
Assumed Liabilities
|
| | | |
|
Schedule 6.8
Stockholders Meeting
|
| | | |
| EXHIBITS | | | | |
|
Exhibit A
Form of Assignment and Bill of Sale
|
| | | |
|
Exhibit B
Form of Patent Assignment
|
| | | |
| | | | | |
| | | | |
| | | | ATRECA, INC. | |
| | | |
By:
/s/ John A. Orwin
Name: John A. Orwin
Title: President and Chief Executive Officer |
|
| | | | IMMUNOME, INC. | |
| | | |
By:
/s/ Clay Siegall
Name: Clay Siegall
Title: President and Chief Executive Officer |
|
| | | | COMPANY | |
| | | | Atreca, Inc. | |
| | | |
Name:
Title: |
|
| | | | PURCHASER | |
| | | | Immunome, Inc. | |
| | | |
Name:
Title: |
|
| | | | STOCKHOLDER | |
| | | | [NAME] | |
| | | |
|
|
| | | | Email: [ ] | |
| |
Name
|
| | |
Class A
Common Stock |
| | |
Class B
Common Stock |
| | |
Company Options
|
| | |
Restricted Stock
Units |
| |
| | | | | | | | | | | | | | | | | | | | |
| | |
Page
|
| |||
| | | | 1 | | | |
| | | | 1 | | | |
| | | | 3 | | | |
| | | | 3 | | | |
| | | | 3 | | | |
| | | | 3 | | | |
| | | | 4 | | | |
| | | | 5 | | | |
| | | | 5 | | | |
| | | | 6 | | | |
| | | | 6 | | | |
| | | | 6 | | | |
| | | | 8 | | | |
| | | | 9 | | | |
| | | | 9 | | | |
| | | | 9 | | | |
| | | | 9 | | | |
| | | | 9 | | | |
| | | | 9 | | | |
| | | | 9 | | | |
| | | | 10 | | | |
| | | | 10 | | | |
| | | | 10 | | | |
| | | | 10 | | | |
| | | | 11 | | | |
| | | | 11 | | | |
| | | | 11 | | | |
| | | | 11 | | | |
| | | | 12 | | | |
| | | | 12 | | | |
| | | | 12 | | | |
| | | | 12 | | | |
| | | | 12 | | | |
| | | | 12 | | | |
| | | | 13 | | | |
| | | | 13 | | | |
| | | | 13 | | |
| | | | Immunome, Inc. | |
| | | |
|
|
| | | | [ ], as Rights Agent | |
| | | |
|
|
Exhibit 107
Calculation of Filing Fee Tables
Schedule 14A
(Form Type)
Atreca, Inc.
(Exact Name of Registrant as Specified in its Charter)
Table 1: Transaction Value
Proposed Maximum Aggregate Value of Transaction | Fee Rate | Amount of Filing Fee | ||||||||||
Fees to Be Paid | $ | 9,379,194.52 | 0.0001476 | $ | 1,384.37 | |||||||
Fees Previously Paid | – | – | ||||||||||
Total Transaction Valuation | $ | 9,379,194.52 | $ | 9,379,194.52 | ||||||||
Total Fees Due for Filing | $ | 1,384.37 | ||||||||||
Total Fees Previously Paid | – | |||||||||||
Total Fee Offsets | – | |||||||||||
Net Fee Due | $ | 1,384.37 |
(i) Title of each class of securities to which transaction applies:
Class A common stock, $0.0001 par value per share, of the Registrant (“Class A common stock”) and Class B common stock, $0.0001 par value per share, of the Registrant (“Class B common stock”).
(ii) Aggregate number of securities to which transaction applies:
Not applicable.
(iii) Per unit price or other underlying value of transaction computed pursuant to Rule 0-11 under the Securities Exchange Act of 1934, as amended (the “Exchange Act”):
Solely for the purpose of calculating the filing fee pursuant to Exchange Act Rule 0-11(c), the underlying value of the transactions (the “Total Consideration”) was calculated based on the sum of: (i) $7,000,000 payable to Atreca, Inc., a Delaware corporation (the “Company”), upon the achievement of certain clinical-based milestone events set forth in, subject to and in accordance with the terms and conditions of, a Contingent Value Rights Agreement substantially in the form attached as Exhibit D to that certain Asset Purchase Agreement (the “Asset Purchase Agreement”), dated December 22, 2023, by and between the Company and Immunome, Inc., a Delaware corporation, and (ii) the product of (a) the highest estimated initial liquidating distribution to the Company’s stockholders of $0.06 per share of Class A common stock and Class B common stock, respectively, and (b) 39,653,242 shares outstanding of Class A common stock and Class B common stock (based on the sum of (i) 38,438,284 shares outstanding of Class A common stock as of April 10, 2024 and (ii) 1,214,958 shares outstanding of Class B common stock as of April 10, 2024). The $5,500,000 payable to the Company at the closing of the Asset Sale (as defined in the attached proxy statement) pursuant to the Asset Sale Agreement is reflected in the Company’s calculation of the highest estimated initial liquidating distribution for purposes of this filing fee calculation. Pursuant to Exchange Act Rule 0-11(c) and Section 14(g) of the Exchange Act, the filing fee equals the product of 0.0001476 multiplied by the Total Consideration.